for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lannett Company, Inc.

LCI.N

Latest Trade

8.68USD

Change

0.19(+2.24%)

Volume

45,906

Today's Range

8.51

 - 

8.74

52 Week Range

4.34

 - 

15.37

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
8.49
Open
8.51
Volume
45,906
3M AVG Volume
33.59
Today's High
8.74
Today's Low
8.51
52 Week High
15.37
52 Week Low
4.34
Shares Out (MIL)
40.34
Market Cap (MIL)
348.90
Forward P/E
7.38
Dividend (Yield %)
--

Next Event

Lannett Company Inc Annual Shareholders Meeting

Latest Developments

More

Lannett Announces Positive Results From Human Clinical Trial Of Biosimilar Insulin Glargine Versus U.S. Lantus

Lannett Company Inc Enters Into A Collaboration And License Agreement With HEC

Lannett Posts Q1 Loss Per Share Of $0.32

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lannett Company, Inc.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Industry

Biotechnology & Drugs

Contact Info

9000 State Rd

+1.215.3339000

http://www.lannett.com/

Executive Leadership

Patrick G. LePore

Independent Chairman of the Board

Timothy C Crew

Chief Executive Officer, Director

John Kozlowski

Chief Financial Officer, Vice President - Finance

John M. Abt

Vice President and Chief Quality and Operations Officer

Maureen M. Cavanaugh

Senior Vice President and Chief Commercial Operations Officer

Key Stats

3.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.6K

2018

0.7K

2019

0.7K

2020(E)

0.5K
EPS (USD)

2017

2.860

2018

3.100

2019

2.350

2020(E)

1.200
Price To Earnings (TTM)
124.68
Price To Sales (TTM)
0.56
Price To Book (MRQ)
1.05
Price To Cash Flow (TTM)
6.12
Total Debt To Equity (MRQ)
226.74
LT Debt To Equity (MRQ)
205.73
Return on Investment (TTM)
0.32
Return on Equity (TTM)
0.27

Latest News

Latest News

BRIEF-Lannett Receives FDA Approval For Dronabinol Capsules

* LANNETT COMPANY INC - RECEIVED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR DRONABINOL CAPSULES USP, 2.5 MG, 5 MG AND 10 MG

BRIEF-Lannett Reports Q3 Adjusted Earnings Per Share $0.80

* LANNETT ANNOUNCES FISCAL 2018 THIRD-QUARTER FINANCIAL RESULTS

BRIEF-Lannett Acquires Portfolio Of Generic Products From Endo International

* LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL

BRIEF-Lannett Appoints Patrick Lepore Chairman Of Board

* LEPORE WILL SUCCEED JEFFREY FARBER, WHO WILL REMAIN A MEMBER OF BOARD Source text for Eikon: Further company coverage:

BRIEF-Lannett Company Files For Potential Mixed Shelf Offering

* LANNETT COMPANY INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2GblSC4) Further company coverage:

BRIEF-Lannett Co Reports Q2 Earnings Per Share $0.37

* LANNETT ANNOUNCES FISCAL 2018 SECOND-QUARTER FINANCIAL RESULTS; REPORTS RECORD REVENUES, STRONG EARNINGS

BRIEF-Lannett Co Voluntarily Pays Down $25 Mln Of Term Loans

* LANNETT COMPANY SAYS $25 MILLION PAY DOWN OF TERM LOANS WILL SAVE CO ABOUT $1.7 MILLION IN ANNUALIZED CASH INTEREST EXPENSE, AT CURRENT RATES Source text for Eikon: Further company coverage:

BRIEF-Lannett Enters Into Consulting Agreement With Former CEO, Bedrosian

* LANNETT ENTERS INTO CONSULTING AGREEMENT WITH FORMER CEO, ARTHUR BEDROSIAN

BRIEF-Lannett Names Timothy Crew To Board Of Directors

* LANNETT COMPANY INC - WITH CREW'S APPOINTMENT, TOTAL NUMBER OF DIRECTORS IS SEVEN Source text for Eikon: Further company coverage:

BRIEF-Lannett Appoints Timothy Crew As CEO

* LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY

BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution

* LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT

BRIEF-Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL

* LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®

BRIEF-Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

* Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance

BRIEF-Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing

* Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing Source text : ( http://bit.ly/2zi8xIn ) Further company coverage:

BRIEF-Lannett Co calls price fixing allegations about a single product named in complaint that co sells "meritless"

* Lannett Company Inc - comments on amended civil generic drug price-fixing complaint

BRIEF-Lannett and Celgene enter into settlement and license agreement related to Thalomid

* Lannett and Celgene enter into settlement and license agreement related to Thalomid

BRIEF-Lannett receives two FDA approvals for Lansoprazole, one each for full prescription and OTC

* Lannett receives two fda approvals for Lansoprazole delayed-release capsules usp, one each for full prescription and OTC

BRIEF-Lannett receives FDA approval for Oxycodone and Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg

* Lannett receives FDA approval for Oxycodone And Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg

BRIEF-Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg

* Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg

BRIEF-Lannett announces dismissal of class action lawsuit

* Lannett Company - judge dismissed in entirety putative class action lawsuit against a multitude of generic drug manufacturers including Lannett Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up